19 May 2013
Keywords: boston, sci, taxus, favorable, tlr, rate, vs
Article | 22 January 2007
US vascular devices maker Boston Scientific says that an independent study demonstrates that its Taxus paclitaxel-eluting stent exhibited a
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 January 2007
17 May 2013
© 2013 thepharmaletter.com